

US dollar amounts shown in the tables below are a convenience translation of the sterling amounts. These tables are unaudited.

Income statement

	H1 2023	H1 2023
	£m	\$m
TURNOVER	14,129	17,422
Cost of sales	(3,875)	(4,778)
Gross profit	10,254	12,644
Selling, general and administration	(4,411)	(5,439)
Research and development	(2,601)	(3,207)
Royalty income	406	501
Other Operating income / (expense)	575	709
Operating Profit	4,223	5,208
Finance income	62	76
Finance expense	(388)	(478)
Share of after tax profit/(loss) of associates and joint venture	(4)	(5)
Profit/(loss) on disposal of interest in associates	1	1
Profit before taxation	3,894	4,802
Taxation	(518)	(639)
Profit after taxation from continuing operations	3,376	4,163
Profit attributable to non-controlling interests from continuing operations	262	323
Profit attributable to shareholders from continuing operations	3,114	3,840
	3,376	4,163
Earnings per share from continuing operations	76.9p	94.8c
Diluted earnings per share from continuing operations	76.2p	94.0c

In the income statement above US dollar results for the six months period ended 30 June 2023 are calculated using average rates for six months ended 30 June 2023.

In the detailed sales tables below US dollar results for the six months ended 30 June 2023 are calculated using average rates for six months ended 30 June 2023

Vaccines turnover – six months ended 30 June 2023

	Total £m	US £m	Europe £m	Inter- national £m	Total \$m	US \$m	Europe \$m	Inter- national \$m
Shingles	1,713	981	457	275	2,113	1,210	564	339
<i>Shingrix</i>	1,713	981	457	275	2,113	1,210	564	339
Meningitis	546	239	220	87	671	294	270	107
<i>Bexsero</i>	412	143	212	57	507	176	261	70
<i>Menveo</i>	125	96	6	23	153	118	7	28
<i>Other</i>	9	-	2	7	11	-	2	9
Influenza	35	1	-	34	43	1	-	42
<i>Fluarix, FluLaval</i>	35	1	-	34	43	1	-	42
Established Vaccines	1,627	662	382	583	2,006	814	471	721
<i>Infanrix, Pediarix</i>	262	142	53	67	323	175	65	83
<i>Boostrix</i>	303	193	63	47	374	238	78	58
Hepatitis	328	181	92	55	404	223	113	68
<i>Rotarix</i>	322	125	61	136	397	154	75	168
<i>Synflorix</i>	138	-	19	119	170	-	23	147
<i>Priorix, Priorix Tetra, Varilrix</i>	107	7	63	37	132	8	78	46
<i>Cervarix</i>	79	-	28	51	97	(1)	35	63
<i>Other</i>	88	14	3	71	109	17	4	88
Vaccines excluding COVID 19 solutions	3,921	1,883	1,059	979	4,833	2,319	1,305	1,209
Pandemic vaccines	142	-	123	19	175	-	152	23
Pandemic adjuvant	142	-	123	19	175	-	152	23
Vaccines	4,063	1,883	1,182	998	5,008	2,319	1,457	1,232

Specialty Medicines turnover – six months ended 30 June 2023

	Total £m	US £m	Europe £m	Inter- national £m	Total \$m	US \$m	Europe \$m	Inter- national \$m
HIV	3,048	1,973	704	371	3,759	2,432	868	459
<i>Dolutegravir products</i>	2,602	1,605	645	352	3,209	1,979	795	435
<i>Tivicay</i>	697	396	135	166	859	488	166	205
<i>Triumeq</i>	766	519	149	98	945	640	184	121
<i>Juluca</i>	313	237	69	7	386	292	85	9
<i>Dovato</i>	826	453	292	81	1,019	559	360	100
<i>Rukobia</i>	52	48	3	1	63	58	4	1
<i>Cabenuva</i>	303	251	45	7	374	310	55	9
<i>Apretude</i>	60	60	-	-	74	74	-	-
<i>Other</i>	31	9	11	11	39	11	14	14
Respiratory / Immunology and Other	1,393	947	224	222	1,717	1,168	276	273
<i>Nucala</i>	771	445	184	142	951	549	227	175
<i>Benlysta</i>	611	501	48	62	753	618	59	76
<i>Other</i>	11	1	(8)	18	13	1	(10)	22
Oncology	287	122	147	18	355	152	181	22
<i>Zejula</i>	231	101	112	18	286	126	138	22
<i>Blenrep</i>	20	(2)	22	-	25	(2)	27	-
<i>Jemperli</i>	36	23	13	-	44	28	16	-
<i>Other</i>	-	-	-	-	-	-	-	-
Specialty Medicines excluding COVID 19 solutions	4,728	3,042	1,075	611	5,831	3,752	1,325	754
Pandemic	31	(1)	1	31	38	(1)	1	38
<i>Xevudy</i>	31	(1)	1	31	38	(1)	1	38
Specialty Medicines	4,759	3,041	1,076	642	5,869	3,751	1,326	792

General Medicines turnover – six months ended 30 June 2023

	Total £m	US £m	Europe £m	Inter- national £m	Total \$m	US \$m	Europe \$m	Inter- national \$m
Respiratory	3,559	1,782	723	1,054	4,389	2,198	891	1,300
<i>Arnuity Ellipta</i>	21	17	-	4	26	21	-	5
<i>Anoro Ellipta</i>	260	120	94	46	321	148	116	57
<i>Avamys/Veramyst</i>	198	-	35	163	244	-	43	201
<i>Flixotide/Flovent</i>	253	159	38	56	312	196	47	69
<i>Incruse Ellipta</i>	79	37	30	12	98	46	37	15
<i>Relvar/Breo Ellipta</i>	562	221	190	151	693	273	234	186
<i>Seretide/Advair</i>	661	245	136	280	815	302	168	345
<i>Trelegy Ellipta</i>	1,076	788	134	154	1,327	972	165	190
<i>Ventolin</i>	376	195	48	133	463	240	59	164
Other Respiratory	73	-	18	55	90	-	22	68
Other General Medicines	1,748	174	367	1,207	2,156	214	453	1,489
Dermatology	185	-	54	131	229	-	67	162
<i>Augmentin</i>	311	-	96	215	383	-	118	265
<i>Avodart</i>	182	-	59	123	225	-	73	152
<i>Lamictal</i>	244	122	55	67	301	150	68	83
Other	826	52	103	671	1,018	64	127	827
General Medicines	5,307	1,956	1,090	2,261	6,545	2,412	1,344	2,789

Commercial operations turnover – six months ended 30 June 2023

	Total £m	US £m	Europe £m	Inter- national £m	Total \$m	US \$m	Europe \$m	Inter- national \$m
Commercial operations turnover	14,129	6,880	3,348	3,901	17,422	8,482	4,127	4,813
<i>Commercial operations turnover excluding COVID 19 solutions</i>	<i>13,956</i>	<i>6,881</i>	<i>3,224</i>	<i>3,851</i>	<i>17,209</i>	<i>8,485</i>	<i>3,974</i>	<i>4,750</i>

Balance sheet

	30-Jun-23 £m	30-Jun-23 \$m
ASSETS		
Non-current assets		
Property, plant and equipment	8,661	10,954
Right of use assets	654	827
Goodwill	6,716	8,494
Other intangible assets	15,531	19,644
Investments in associates and joint ventures	64	81
Other investments	1,286	1,627
Deferred tax asset	5,799	7,335
Other non-current assets	1,402	1,773
Total non-current assets	40,113	50,735
Current assets		
Inventories	5,512	6,972
Current tax recoverable	319	403
Trade and other receivables	6,776	8,571
Derivative financial instruments	164	207
Current equity investments	3,250	4,111
Liquid investments	114	144
Cash & cash equivalents	3,140	3,971
Assets held for sale	73	92
Total current assets	19,348	24,471
TOTAL ASSETS	59,461	75,206
LIABILITIES		
Current liabilities		
Short-term borrowings	(5,921)	(7,489)
Contingent consideration liabilities	(947)	(1,198)
Trade and other payables	(13,951)	(17,645)
Derivative financial instruments	(136)	(172)
Current tax payable	(544)	(688)
Short term provisions	(609)	(770)
Total current liabilities	(22,108)	(27,962)
Non-current liabilities		
Long-term borrowings	(15,553)	(19,672)
Corporation tax payable	(76)	(96)
Deferred tax liabilities	(500)	(632)
Pension and other post-employment benefits	(2,337)	(2,956)
Other provisions	(544)	(688)
Contingent consideration liabilities	(5,280)	(6,678)
Other non-current liabilities	(904)	(1,143)
Total non-current liabilities	(25,194)	(31,865)
TOTAL LIABILITIES	(47,302)	(59,827)
NET ASSETS	12,159	15,379
EQUITY		
Share Capital	1,348	1,705
Share premium account	3,450	4,364
Retained earnings	6,418	8,117
Other reserves	1,475	1,866
Shareholders' equity	12,691	16,052
Non-controlling Interests	(532)	(673)
TOTAL EQUITY	12,159	15,379

US dollar amounts shown in the balance sheet above are calculated using closing rate at 30 June 2023.